Health Care • Biotechnology: Pharmaceutical Preparations
$22.53 ▲ +0.30
(+1.35%)
MKT CAP: $3.80B • VOL: 3.37M
52W L $7 52W H $34
TNGX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $62.4M | $42.1M | $36.5M |
| YoY Revenue Growth % | +48.3% | +15.2% | — |
| Gross Profit | $27.4M | $18.5M | $16.1M |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$111.3M | -$145.6M | -$114.2M |
| Operating Margin % | -178.4% | -346.1% | -312.6% |
| Net Income (GAAP) | -$101.6M | -$130.3M | -$101.7M |
| EBITDA (Normalized) | -$110.5M | -$145.0M | -$112.9M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$138.9M | -$131.5M | -$118.0M |
| Capital Expenditures (CapEx) | $1.0M | $754.0K | $1.6M |
| Free Cash Flow (FCF) | -$139.9M | -$132.3M | -$119.6M |
| FCF Margin % | -224.3% | -314.4% | -327.5% |
| Return on Invested Capital (ROIC %) | -34.1% | -45.0% | -7.1% |
| Cash & Short-Term Equivalents | $112.3M | $69.5M | $229.8M |
| Total Debt (Short + Long Term) | $23.6M | $52.6M | $488.9M |
| Total Stockholders' Equity | $346.2M | $199.5M | $1.00B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR TNGX.